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Abstract

Immune checkpoint blockade has demonstrated great potential in activating antitumor immunity.
Ipilimumab is a monoclonal antibody which targets cytotoxic T-lymphocyte antigen-4. CTLA-4
belongs to the CD28 class of receptors and is found on the surface of CD4+ and CD8+ T cells.
CTLA-4 acts to suppress the immune system when bound to CD80 and CD86 receptors on
antigen presenting cells. Ipilimumab, or anti-CTLA-4, has shown to be effective in significantly
extending the survival of patients with metastatic melanoma. However, systemic delivery of
Ipilimumab also induces significant side effects such as: colitis, dermatitis, uveitis, and
hypophysitis. In order to minimize toxicity, we and others have hypothesized that intratumoral
administration of anti-CTLA-4 at a lower dose can have the same antitumor efficacy as systemic
delivery but without the toxicity. This work begins with an investigational pilot study to
determine the efficacy of anti-CTLA-4 by delivering 60 µg of anti-CTLA-4 to a group of mice
and measuring the tumor growths when compared to an untreated control group. Once efficacy
had been demonstrated, a dosing study was conducted to identify an optimal intratumoral dosage
delivered to murine models. The groups were given doses of either 30 µg, 60 µg, or 120 µg.
From this study, the 60 µg group had the lowest average tumor size of 300 mm3. Our lab has
previously demonstrated that IL-12 co-formulated with chitosan has demonstrated prolonged
intratumoral retention therefore, 60 µg of anti-CTLA-4 was co-formulated with a chitosan
solution to investigate the efficacy in a delivery vehicle. Finally, 60 µg of anti-CTLA-4 was
delivered in a proprietary hydrogel alone and with Interleukin-12 to examine the effects of
controlled release.

2

1. Introduction

A mutation in the sequence of DNA in a gene can lead a cell to become cancerous. Cancer can
be quickly summarized as uncontrolled cell division. This cell division that occurs in a
cancerous cell will lead to the development of a solid tumor within the body. Definitively curing
this disease has proved troublesome as scientists have attempted surgery, radiation, and
chemotherapy as the main treatment routes for patients. Currently, cancer trails only
cardiovascular disease as the largest cause of death among individuals in the world1. Pancreatic
cancer has a mortality rate near 85%. In addition to being characterized as one of the most
aggressive cancers, about 44,000 new cases of pancreatic cancer are diagnosed every year.
Pancreatic cancer has a 5 year survival rate of less than 5% while the median time of patient
survival after diagnosis barely reaches six months. Pancreatic cancer is highly metastatic and
resistant to drug treatments which helps to explain the poor survival rate2,3.

Recently, a new method of cancer treatment has emerged in the form of immune checkpoint
inhibitors. This treatment utilizes the machinery found in the immune system to attack and
destroy cancer cells. Anti-CTLA-4 is a monoclonal antibody which targets cytotoxic Tlymphocyte antigen-4. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an immunoglobulin
protein found on the surface of CD4+ and CD8+ T cells and is part of the CD28 class of protein
receptors. CTLA-4 delivers an inhibitory signal to T cells when bound to CD80 and CD86
expressed on antigen presenting cells. Anti-CTLA-4, or Ipilimumab, is an immune checkpoint
inhibitor currently approved to treat metastatic melanoma. By blocking this interaction, antiCTLA-4 essentially eliminates the ability of CTLA-4 to send inhibitory signals to T cells and
thus activates T cell function4,5. Yet, anti-CTLA-4 therapy has shown to induce severe
autoimmune effects in patients such as colitis, dermatitis, uveitis, and hypophysitis making
3

effective delivery of dosage and treatment difficult in clinical trials4,5. In clinical trials for
Ipilimumab, Bristol Myers Squibb released a Phase III trial that showed improved life
expectancy of over six hundred patients diagnosed with metastatic melanoma. Ipilimumab was
given at 3 mg/kg early on during investigation only to show little efficacy, however, reevaluation
at 10mg/kg of Ipilimumab systemic delivery with immune factors showed an increased survival
by over 2 months, a significant increase5. Sandin et al. locally delivered anti-CTLA-4 to
pancreatic tumors in murine models and have demonstrated that lower dose peritumoral
injections of the antibody performed similar to that of the standard method of treatment of antiCTLA-4 by higher dose systemic delivery5. In a paper published by Fransen et al., a slow
release delivery system of Montanide ISA-51 was delivered with anti-CTLA-4 subcutaneously in
murine models to treat MC-38 tumor cells. The results of this experiment show that the slow
release Montanide solution with anti-CTLA-4 was effective in activating antitumor activity
while minimizing autoimmune side effects6. Both of these studies are unable to effectively
eliminate the respective tumors completely5,6.

In this study, we hypothesize that direct intratumoral injections of anti-CTLA-4 will prove more
effective in restricting tumor growth. Additionally, we believe that delivering this antibody
intratumorally in a retentive vehicle will allow for a prolonged presence at the tumor site and will
enhance the antitumor response. We have also delivered anti-CTLA-4 in combination with
interluekin-12 (IL-12) in a hydrogel intratumorally. IL-12 is a pro-inflammatory cytokine
produced by dendritic cells and macrophages. Our lab has demonstrated the efficacy of IL-12
delivered intratumorally in a chitosan hydrogel delivery vehicle. Our lab has also demonstrated
tumor rejection in mice previously treated with IL-12 in chitosan solution7. Chitosan is a non-
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toxic, biodegradable polysaccharide which can be derived from the exoskeletons of shellfish7.
We believe that the combination therapy will inhibit the growth of pancreatic tumors while the
IL-12 component will provide an additional level of immune activation.

The goal of this study is to determine the effectiveness of anti-CTLA-4 as a potential
immunotherapy when injected intratumorally in concert with IL-12 in a slow release controlled
hydrogel. The lower dose of intratumoral delivery not only will reduce autoimmune side effects,
but also reduce cost for the patient. Ipilimumab treatment currently costs $120,000 for a four
dose injection schedule8. By demonstrating that local delivery is just as effective in eliminating
tumors, Ipilimumab treatment could be administered at lower doses and thus lower costs.
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2. Materials and Methods
2.1 Cell Line Preparation and Maintenance
The Panc02 cell line was thawed from liquid nitrogen storage. Panc02 cells were then cultured
in a T-25 culture flask with McCoy’s 5A media supplemented with 10% fetal bovine serum and
antibiotics at 37°C and 5% CO2. Cells were passaged twice weekly or once 80%-90%
confluency was reached in the flask. One week prior to beginning of animal studies, cell culture
would be expanded into a T-75 culture flask to ensure sufficient cell numbers. Panc02 cells were
counted using a 1:10 dilution of cell suspension and Trypan Blue. The mixture would then be
placed onto a hemocytometer for cell counting. The four corner squares of the hemocytometer
were used for cell counts. Final cell number calculations are as follows in Equation 1.
!"##$
%&

=

!"##$ )*+,-".
/

∗ 10 ∗ 10/

(Equation 1)

Viable cells counted did not take up the Typan Blue stain and cells overlapping only the top and
left boundaries of a square were included in the count. Panc02 cells were passaged at a dilution
of 1:10 in a new T-25 culture flask.
2.2 Inoculation and Tumor Measurements
For tumor inoculation, all mice were anesthetized by administering a 50 µL intraperitoneal
injection of 1:1:4.6 mixture of Ketamine, Xylazine, and deionized water, respectively. Mice in
each study were given 2.5×107 Panc02 cells in 100 µL of PBS subcutaneously to the shaven
right flank on day 0. After formation of palpable tumors, usually day 5 after implantation,
treatment regime began. All intratumoral injections that were given were administered in a
subcutaneous fashion, however, treatment was injected once syringe needle penetrated the tumor.
In all experiments, two-week old female C57BL/6J mice were ordered from Jackson
Laboratories for use. Tumor measurements and examination of health were made twice weekly.
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Tumors were measured in two dimensions and the following equation was used when calculating
volume:
9

:
𝑉 = 𝑙$<*=𝑙#*,>
:

(Equation 2)

The previous equation does assume the tumors are of ellipsoid shape. Mice were sacrificed by
cervical dislocation after tumor volumes eclipsed 1000 mm3. Anti-CTLA-4 antibody (clone
9D9) was ordered from Bio X Cell.
2.3 Pilot Study
In the initial pilot study to investigate the antitumor activity of anti-CTLA-4, two groups of five
mice were used. Treatments began on day 5 after implantation and repeated on days 8 and 11
and given twice weekly until the conclusion of the experiment. Control mice were given PBS in
50 µL. Antibody treatment group was administered at 30 µg of antibody in 50 µL of PBS
solution.
2.4 Dosing Study
The dosing study was expanded to four treatment groups. Intratumoral treatments occurred on
days 5, 8, and 11. The control group of 3 mice was given 50 µL of PBS. The next group was
given 30 µg of anti-CTLA-4 in 50 µL of solution to four mice. Five mice participated in both the
60 µg and 120 µg groups.
2.5 Chitosan Co-Formulation
In the first co-formulation study, five mice per group were used. This study consisted of three
groups of mice: A control, anti-CTLA-4 only, and anti-CTLA-4 co-formulated with a chitosan
hydrogel. Treatments were administered on days 5, 12, and 19. Again, control group mice were
administered intratumoral PBS injections. Anti-CTLA-4 only mice received a 60 µg treatment
and finally anti-CTLA-4 co-formulated with chitosan received a 50 µL intratumoral injection of
7

a chitosan hydrogel and 60 µg of anti-CTLA-4. The chitosan hydrogel was prepared by
dissolving purified lyophilized chitosan in PBS to 1% weight by weight. Anti-CTLA-4 was then
added to appropriate concentration.
2.6 Combination Immunotherapy
In the final study, six groups of 5 mice were used to investigate the effects of combination
immunotherapy of anti-CTLA-4 and IL-12. Again, a control group consisting of 5 mice were
administered 50 µL of PBS intratumorally. Intraperitoneal injections of 60 µg of anti-CTLA-4
were given to the next group. An additional group new to any of the studies was a hydrogel only
group. 50 µL of hydrogel was administered intratumorally to mice. Additionally, a group 60 µg
of anti-CTLA-4/hydrogel and a group of 1 µg of IL-12/hydrogel were given intratumoral
injections. Finally, a combination group of 60 µg of anti-CTLA-4, 1 µg of IL-12, and hydrogel
were delivered intratumorally in combination. Treatments were given on days 7, 14, and 21 or
once weekly due to the retention of the hydrogel. This was done to ensure accurate tumor
measurements.
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3. Results
3.1 Demonstration of Efficacy
Since anti-CTLA-4 is new to our lab, a pilot study was performed to demonstrate the efficacy of
anti-CTLA-4 treatment. After conclusion of the study, growth curves (Figure 1A) and average
tumor volumes (Figure 1B) were constructed between the two groups: anti-CTLA-4 treated and
untreated.

Figure 1: Tumor growths from initial pilot study of anti-CTLA-4 efficacy. n=4

Mice from the study were sacrificed on day 41 as tumor volumes had eclipsed 1000 mm3 for the
untreated group and the treated group approached that threshold. Additionally, anti-CTLA-4
treated mice had shown signs of minimal dermatitis. None of the mice exhibited any weakness
or abnormal behavior. From Figure 1, the untreated group had an average tumor volume of 1364
mm3 and the anti-CTLA-4 treated group showed reduced average tumor size of 960 mm3. The
standard deviations of the groups were: 412 mm3 for the untreated group and 671 mm3 for the
anti-CTLA-4 treated group. Individual growth curves were also generated but are not shown
here.
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3.2 Anti-CTLA-4 Dosing Study
Following the pilot study, our lab was confident that anti-CTLA-4 had some antitumor efficacy.
Because it was our first time using anti-CTLA-4, a dosing study was needed to determine the
optimal dose. Previous studies that had delivered anti-CTLA-4 locally used doses ranging from
30 µg to 90 µg and used a dose of 200 µg of anti-CTLA-4 for systemic (intraperitoneal)
injections. However, the study was not delivered directly into the tumor. Therefore, the dosing
study consisted of four groups: a control (PBS), a 30 µg group, a 60 µg group, and a 120 µg
group. Results from the dosing study are shown below in Figure 2.

Figure 2: Growth curve of dosing study. Groups were given bi-weekly injections. n=3-5

All remaining mice were sacrificed on day 46 at the conclusion of the study. On day 17, a
mouse in the PBS group was accidentally killed due to a bad injection resulting in an air
embolism. The PBS group, as expected, had the highest average tumor volume at the conclusion
of the study with an average size of 1311 mm3. The 120 µg group had an average tumor size of
839 mm3 followed by the 30 µg group at 609 mm3. The 60 µg group yielded the smallest
average tumor size at 304 mm3, over half that size of the next closest group. Standard deviations
10

were 31.66 mm3, 429 mm3, 389 mm3, and 587 mm3 for the PBS, 30 µg, 60 µg, and 120 µg
groups, respectively.

3.3 Co-Formulation of Anti-CTLA-4 with Chitosan
After determining that an optimal intratumoral dose of anti-CTLA-4 was 60 µg, formulation of
the antibody with chitosan was investigated. Previous studies had used a Montanide emulsion as
a delivery vehicle for anti-CTLA-4. However, this solution was delivered subcutaneously as
opposed to intratumorally. Our lab has previously demonstrated that chitosan leads to increased
retention at the tumor site7. The 60 µg dose was combined with a chitosan hydrogel and injected
intratumorally. From the measurements the average and individual growth curves generated are
shown in Figure 3 and 4.

Figure 3: Individual growth curves of treatment groups. n=5

From these results, the anti-CTLA-4/chitosan treated group showed the smallest sized tumors.
This group was the only to have at least one mouse eliminate its tumor. Earlier in the study at
day 23, 60% of the anti-CTLA-4/chitosan group did not have any palpable tumor mass. Anti-
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CTLA-4 treatment still shows to restrain tumor growth when compared to PBS treated mice.
The average tumor volumes between groups were calculated and shown in Figure 4.

Figure 4: Average tumor volume by group. n=5

The average tumor size for the PBS mice once again eclipsed the 1000 mm3 barrier with the final
average tumor size of 1021 mm3. The 60 µg anti-CTLA-4 only group had a final average tumor
volume of 763 mm3 while the 60 µg anti-CTLA-4/chitosan group had the lowest tumor sizes at
an average of 407 mm3. It is important to note that one mouse from the co-formulated group
eliminated its tumor and two additional mice were lacking tumors until day 23 and day 42 of the
50 day study. The mice were examined periodically during the study and all mice seemed to be
free of dermatitis and abnormal behavior. The co-formulation group did develop sores at the
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tumor site after injections that eventually healed. Selected mice from each group are shown
below in Figure 5.

Figure 5: Selected mice from day 18. A: PBS Group B: Anti-CTLA-4 C: Anti-CTLA-4/Chitosan

From Figure 5c the sores that were mentioned previously can be faintly seen as a scab. This
severity of sore was representative of the group, however, bleeding was recorded in one of the
mice. Overall, the results from this study supported initial hypothesis.

3.4 Combination Therapy of Anti-CTLA-4 and IL-12 in a Novel Hydrogel
From the conclusion of the previous study, further investigation into hydrogel delivery was
needed. Our lab has developed a novel controlled release hydrogel. We wanted to utilize this
hydrogel to deliver anti-CTLA-4. Additionally, we wanted to initiate a combination study
including IL-12 and anti-CTLA-4 delivered in the gel. In Figure 6, growth curves are shown.
This study was actually repeated as the first attempt was done with mice that already had severe
dermatitis. Initially, we proceeded to run the experiment in hopes that the mice would recover
from their skin condition. Over the course of the experiment the mice were monitored
extensively and never regained normal skin health. By day 14, the mice had scabbing from dry,
13

irritated skin and the control mice did not grow tumors at the same rate as we had seen before.
Therefore, we decided to improve on the experiment by performing it again with healthier mice
and additional groups so as to measure the effects of the gel alone.

Figure 6: Growth curves from the Combination Immunotherapy study. n=5

The most notable result of this study is that after 44 days, the combination group had no
detectable tumor mass. In addition, the IL-12/Gel group performed similarly but had one mouse
develop and sustain a very small tumor. Average tumor volumes for the PBS, intraperitoneal
anti-CTLA-4, Gel only, anti-CTLA-4/Gel were 715 mm3, 477 mm3, 1065 mm3, and 911 mm3,
respectively.
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Figure 7: Individual growth curves for all treatment groups participating in the combination immunotherapy study.

Figure 7 shows the individual growth curves of the mice participating in the combination study.
The group administered anti-CTLA-4 alone, intraperitoneally, developed severe dermatitis and
loss most of their fur coat two weeks into the study.
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4. Discussion
4.1 Demonstration of Efficacy
The efficacy of anti-CTLA-4 has been shown to be dependent on whether or not tumor invading
myeloid cells are present. The effects of these myeloid cells are that FcγR crosslinking occurs
which results in the cytolytic degradation of regulatory T cells that express CTLA-4. Since
pancreatic adenocarcinoma is known to have abundant myeloid cell invading activity, it is
possible that the Panc02 cell line would respond promisingly to CTLA-4 blockade9. The results
from this quick pilot study confirmed the antitumor activity associated with anti-CTLA-4. The
bi-weekly injections allowed for anti-CTLA-4 to maintain the blockade over a longer duration
and to replenish antibody concentrations after clearance of the first dose. The lower average
tumor size confirms that anti-CTLA-4 has potential in restricting tumor size in the Panc02 cell
line. The current standard of Ipilimumab treatment for patients is by systemic route, however
many patients experience autoimmune side effects like dermatitis4. It is possible that if the cause
of these adverse side effects are the reduction of regulatory T cells, a local and controlled release
delivery method could potentially limit these side effects.
4.2 Anti-CTLA-4 Dosing Study
Results from the dosing study were surprising in that the highest dosage group, 120 µg, had the
highest tumor volumes when compared to the other anti-CTLA-4 treatment groups. From
previous studies, local delivery at 60 µg was delivered peritumorally. This reaffirmed the
decision that the 60 µg dose would be optimal moving forward with future experiments. It was
unexpected that the highest dosage group, 120 µg of anti-CTLA-4, failed to restrain tumor
growth and ranked last among treatment groups for tumor size. The initial hypothesis was that
the higher dose would have a greater and more intense effect intratumorally. A similar
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phenomena was observed in Sandin et al., where treatment frequency and dosage was analyzed
in their study. Their findings included an increase in the levels of regulatory T cells found in the
serum of the mice treated with higher doses of CTLA-4 blockade. A possible explanation in this
finding was a suppression assay performed by Sandin et al. finding that regulatory T cells have
the potential to down regulate the proliferation of responder cells and thus lower immune
response in the tumor environment5. In Sandin et al., where treatments were given
peritumorally, our study wanted to investigate the enhanced effects of direct intratumoral
delivery5. We hypothesized that due to pancreatic tumors having a thick fibrotic stroma, local
injections near the tumor may not have the same effect as drug permeability at the stroma by
administering the treatments directly into tumors10.
4.3 Co-Formulation of Anti-CTLA-4 with Chitosan
This study returned promising results as during the treatment scheduling, the mice treated with
the co-formulated gel showed almost no tumor growth. Two mice eliminated their tumors
during the treatment regime however once the treatments were terminated, a tumor in one of the
mouse began to grow rapidly. The administered chitosan hydrogel was noted and physically
detected in the flanks of the mice up to 6 days following the treatment. This indicates that the
chitosan was able to maintain a sustained delivery of anti-CTLA-4 for an extended period of
time. However, sores and ulcers did develop right at the tumor sites for the groups treated with
the hydrogel. It is possible that the intensity of the immune response to the anti-CTLA-4
administration could have caused the ulceration. We hypothesize that the prolonged sustained
delivery correlates to an increase in antitumor activity. When compared to a study done by
Sandin et al., tumor growth showed to only be restrained in groups treated peritumorally with
anti-CTLA-4 against Panc02 tumors even with increased treatment days while when delivered in
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a chitosan hydrogel intratumorally, tumor growth would cease in mice and in some cases
completely regress as long as the treatments were delivered5. A study performed by Fransen et
al. showed that the delivery of anti-CTLA-4 in a slow release Montanide emulsion
subcutaneously only restrained tumor growth in MC-38 tumors expressing ovalbumin6. While
the tumor is different from the Panc02 cell line used in this study, we are still able to demonstrate
that intratumoral delivery is slightly more effective in that the average tumor volumes for the
study performed by Fransen et al. were just short of 200 mm3 on day 35 while our study showed
that in the same time frame, average tumor volumes were 109 mm3 with two mice completely
lacking tumors. One of the major critiques we had for this experiment was that there was no
group to test the effects of the chitosan hydrogel on tumor growth. Chitosan has been shown to
have some biological activity therefore, the study needed to examine the effects of a chitosan
hydrogel on pancreatic tumor growth11. Also of note, in Sandin et al., their findings show that
additional treatment frequency does not influence the growth of the tumor5. Our findings in this
study contradict that claim. Mice treated with the co-formulation of anti-CTLA-4 and chitosan
had no detectable tumor mass in 4 of the 5 mice, however after administration of the last dose on
day 19, tumors began to grow. This slow release of anti-CTLA-4 in the tumor may cause a
constant immune response that may be more effective than a single dose that may be cleared
from the system in as little as twenty four hours.
4.4 Combination Therapy of Anti-CTLA-4 and IL-12 in a Novel Hydrogel
The results of the combination study show that the combination of anti-CTLA-4, IL-12, and a
hydrogel provided complete response in all mice treated. Five out of five mice were completely
cured of any palpable tumor mass in the combinatory group even after treatments were
terminated. These are slightly better results than with the IL-12/Gel group in which all but one
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mouse completely responded. Our lab has demonstrated similar results in mice using IL-12 and
a chitosan based hydrogel7. Figure 7 shows the individual growth curves of the IL-12/Gel group
and it is notable that the one mouse that developed a tumor maintained a relatively consistent
mass and behaves benign. In addition to the tumor growing at a slow rate, it is relatively small.
Our results also show that the gel group performed similar to the control, however the average
tumor volume in the Gel Only group was greater than that of the control treated with PBS.
Furthermore, the anti-CTLA-4/gel treated group had very large tumors. This may provide some
support about the dosing of anti-CTLA-4. The immune response that was induced in the antiCTLA-4/gel group could have been so great that regulatory T cells could have been recruited to
the site and suppressed the immune response5. Nonetheless, as far as efficacy goes, this study
does demonstrate that IL-12 is more effective in treated pancreatic tumors as it showed to much
less toxic and had a complete response rate of 80%. However, local delivery of anti-CTLA-4
confirmed its toxicity and ability to induce adverse autoimmune related side effects when
delivered systemically. All five mice in the intraperitoneal injection group had varying levels of
dermatitis and displayed ill behaviors while most of the anti-CTLA-4 groups treated
intratumorally sustained minor ulceration at the tumor site.
4.5 Future Direction
Following the conclusion of the combination study, rechallenge studies will be performed to see
if any cured mice have retained immunity against Panc02. Our lab has previously shown mice
treated and cured with IL-12 and chitosan maintain immunity against the rechallenged cell lines7.
We hypothesize that with the addition of IL-12 in the hydrogel treatments, some of these mice
will have immunity when rechallenged on the left flank. Additionally, serum analysis should be
performed in order to investigate anti-CTLA-4 blood concentration of dose levels of anti-CTLA-
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4 when delivered in a hydrogel vehicle. Additionally, it has already been shown that patients
receiving anti-CTLA-4 intravenously show increased regulatory T cell concentrations12.
Therefore, seeing the effect of regulatory T cell levels in response to treatment with a hydrogel
and having a prolonged immune response should be investigated in order to determine more
appropriate doses for these delivery vehicles.

5. Conclusions
In conclusion, anti-CTLA-4 is a promising drug belonging to a class of therapeutics that has
potential to revolutionize cancer treatments. The toxicity of anti-CTLA-4 is quite evident by the
murine models we have used and more work should be done in order to reduce the toxicity levels
such as delivery method. In this study, we have shown that a lower dose of anti-CTLA-4 is more
effective in restraining tumor growth than when compared to a systemic delivery method. Not
only is the antitumor activity treated in mice equal and perhaps more effective in the locally
delivered groups when compared to the systemic group, but the mice treated locally also showed
much milder side effects as a result of the treatment. Ulceration was the most common side
effect in the mice treated locally. When compared to IL-12, anti-CTLA-4 performs much worse
when delivered in a hydrogel based delivery vehicle. As the results show, the IL-12 group was
much more effective in eradicating tumors whereas, anti-CTLA-4 in hydrogel could only restrain
growth for a short period. Additionally, tumors that are more difficult to access would be able to
be delivered with image guided and stereotactic injections. For tumors that are readily
accessible, treatment is very favorable as the treatment can be made and injected bedside. The
future of anti-CTLA-4 therapy to treat tumors may be dependent on how well the toxicity and
side effects of the drug can be managed.
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